Name: 2018 Joint Statistical Meetings
Start: 2018-07-28T07:00:00+00:00
End: 2018-08-02
Location: Vancouver Convention Centre

Keyword Search

Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme

Keyword Search Criteria: Treatment returned 154 record(s)

Sunday, 07/29/2018

Nonparametric Causal Effects Based on Incremental Propensity Score Interventions
Edward Kennedy, Carnegie Mellon University; Matteo Bonvini, Carnegie Mellon University

Quasi-Oracle Estimation of Heterogeneous Treatment Effects
Xinkun Nie, Stanford University; Stefan Wager, Stanford University

Network Meta-Analysis of Disconnected Networks: How Dangerous Are Random Baseline Treatment Effects?
Audrey Béliveau, University of Waterloo; Sarah Goring, SMG Outcomes Research; Robert W Platt, McGill University; Paul Gustafson, University of British Columbia

Matching Methods for Evaluating the Effect of a Time-Dependent Treatment on the Survival Function
Danting Zhu, University of Michigan; Douglas E. Schaubel, University of Michigan, Ann Arbor

High-dimensional Cost-constrained Regression via Non-convex Optimization
Yufeng Liu, University of North Carolina at Chapel Hill
2:05 PM

Statistical Development in Addressing Delayed Treatment Effect or Crossing Survival Curves in Immuno-Oncology Clinical Trials
Huyuan Yang, Takeda Oncology Pharmaceutical
2:20 PM

Quantile-Optimal Treatment Regimes
Lan Wang, University of Minnesota; Yu Zhou, University of Minnesota; Rui Song, North Carolina State University; Ben Sherwood, University of Kansas
2:25 PM

Regularization and Aliasing in the Estimation of Treatment Effect Moderation
Paul Richard Hahn, Arizona State University ; Carlos Carvalho, University of Texas; Jared S Murray, University of Texas at Austin
2:25 PM

Meta-Analysis for the Adjuvant Treatment in Renal Cell Carcinoma
Weichao Bao, Novartis Pharmaceuticals Corporation
2:50 PM

Matching Methods for Evaluating the Effect of a Time-Dependent Treatment on the Survival Function
Danting Zhu, University of Michigan; Douglas E. Schaubel, University of Michigan, Ann Arbor
3:45 PM

Design and Analysis of Survival Trials with Treatment Crossover
Xiaodong Luo, Sanofi
4:25 PM

Q-Learning for Dynamic Treatment Regimes on CODIACS Vanguard Randomized Controlled Trial
Eun Jeong Oh, Columbia; Min Qian, Columbia University; Ying Kuen Ken Cheung, Columbia University
4:35 PM

Causal Estimands and Confidence Intervals Associated with Wilcoxon-Mann-Whitney Tests in Randomized Experiments
Michael Fay, National Institute of Allergy and Infectious Diseases; Erin Gabriel, Karolinska Institute; Joanna H Shih, National Cancer Institute; Dean Follmann, NIAID; Erica H Brittain, National Institute of Allergy and Infectious Diseases
4:35 PM

A Single-Index Model with Multiple-Links
Hyung Park, Columbia University; Eva Petkova, NYU School of Medicine; Thaddeus Tarpey, Wright State University; Todd Ogden, Columbia University
5:05 PM

Propensity Score Stratification: Are We Doing it Wrong?
Roland Matsouaka, Duke University School of Medicine
5:20 PM

Monday, 07/30/2018

Statistical Challenges in Developing Data-Driven Discovery, Diagnosis, and Treatment of Psychiatric Diseases
Thaddeus Tarpey, Wright State University

Add a Patient Selected Treatment Arm in a Randomized Trial
Xueliang Pan; Lai Wei, The Ohio State University; Jill Heathcock, The Ohio State University

Assessing Treatment Benefit in Patient-Centric Study Designs
Jagadish Gogate, Johnson & Johnson-Janssen R&D

Quantile-Optimal Treatment Regimes with Censored Data
Yu Zhou, University of Minnesota; Lan Wang, University of Minnesota; Rui Song, North Carolina State University

Embedding Observational Studies into Hypothetical Fractional-Factorial Experiments
Nicole Pashley, Harvard University; Marie-Abele Bind, Harvard University

Using Validation Data to Adjust the Inverse Probability Weighting Treatment Effect Estimator for Misclassified Treatment
Danielle Braun, Harvard T. H. Chan School of Public Health; Corwin Zigler, Harvard T.H. Chan School of Public Health; Francesca Dominici, Harvard T. H. Chan School of Public Health; Malka Gorfine, Tel Aviv University

Estimating Average Causal Treatment Effects Utilizing Fractional Imputation When Confounders Are Subject to Missingness
Nathaniel Corder, North Carolina State University; Shu Yang, North Carolina State University

A Comparison of Methods to Estimate Survival Curves Under Time-Varying Treatments
Lucia C. Petito, Harvard T.H. Chan School of Public Health; Sonja A. Swanson, Erasmus Medical Center; Miguel Hernan, Harvard School of Public Health

Gaussian Process Propensity Scores for Multiple Treatment Regimes
Brian Vegetabile, UC Irvine; Daniel L. Gillen, University of California, Irvine; Hal Stern, University of California, Irvine

Intravenous Fluid Treatments for Ebola Patients: The Risk and the Reward
Derrick Yam, Brown University; Tao Liu, Brown University; Adam Levine, Brown University; Adam Aluisio, Brown University; Shiromi Peters, International Medical Corps; Suzanne Averill, International Medical Corps; Stephen Kennedy, Ministry of Health, Liberia; Fodey Sahr, Sierra Leone Ministry of Defence; Jillian Peters, Brown University; Daniel Cho, Brown University

Estimating Causal Effect by Difference in Difference via Random Forest
Tomoshige Nakamura, Graduate School of Science and Technology, Keio University; Mihoko Minami, Keio University

Leveraging Multiple Study Designs and Statistical Methods to Evaluate Comparative Effectiveness of Asthma Medications
Tebeb Gebretsadik, Vanderbilt University Medical Center; Pingsheng Wu, Vanderbilt University; Rees L Lee, U. S. Navy; Amber M Evans, Health ResearchTX LLC; Tan Ding, Vanderbilt University Medical Center; Nicholas M Sicignano, Health Research Tx ; Ann Wu, Harvard Medical School; Carlos Iribarren, Kaiser Permanente Division of Research; Butler Melissa, Kaiser Permanente; Chang Yu, Vanderbilt University Medical Center; William Dupont, Vanderbilt University Medical Center; Christina Fox, Health ResearchTx; Tina V Hartert, Vanderbilt University Medical Center

Shared-Parameter G-Estimation of an Optimal Adaptive Treatment Strategy for Rheumatoid Arthritis
Erica E.M. Moodie, McGill University; Michael Wallace, University of Waterloo
8:35 AM

Building Representative Matched Samples in Large-Scale Observational Studies with Multivalued Treatments
Jose Zubizarreta, Harvard University
8:35 AM

Individualized Treatment for Time-To-Event Outcomes with BART
Brent Logan, Medical College of Wisconsin
8:35 AM

Non-Parametric Bayesian Methods for Causal Inference with Multiple Treatments
Michael Lopez , Skidmore College ; Liangyuan Hu, Icahn School of Medicine at Mount Sinai; Chenyang Gu, Harvard Medical School
8:35 AM

Learning Individualized Treatment Rules from Electronic Health Records Data
Yuanjia Wang, Columbia University
9:00 AM

Nonparametric Regression Models of Multilevel, Heterogeneous Treatment Effects: The National Study of Learning Mindsets
Carlos Carvalho, University of Texas; Jared S Murray, University of Texas at Austin; Paul Richard Hahn, Arizona State University ; David Yeager, The University of Texas at Austin; Elizabeth Tipton, Columbia University
9:00 AM

Quantile-Optimal Treatment Regimes with Censored Data
Yu Zhou, University of Minnesota; Lan Wang, University of Minnesota; Rui Song, North Carolina State University
9:15 AM

Assessment of a Treatment Effect for Recurrent Event Data in the Presence of a Terminal Event
Philip Hougaard, Lundbeck
9:15 AM

Rank Score Test for Regional Quantiles Treatment Effect Detection
Yuan Sun, University of Michigan; Xuming He, University of Michigan
9:20 AM

Variance of Treatment Effect, an Important Yet Difficult Parameter
Jonathan Levy, UC Berkeley
9:20 AM

Poly-Matching for Observational Studies: A Comparative Trauma Care Study
Bo Lu, The Ohio State University
9:25 AM

Comparison of Event Rates Between On- and Off-Drug Treatment Periods for a Recurrent Adverse Event
Brenda Crowe, Eli Lilly & Co.; Haoda Fu, Eli Lilly and Company; Yebin Tao, Eli Lilly and Company
9:35 AM

Sample Size Considerations for Comparing Dynamic Treatment Regimens in a Sequential Multiple-Assignment Randomized Trial with a Continuous Longitudinal Outcome
Nicholas J Seewald, University of Michigan; Kelley M Kidwell, University of Michigan; James R McKay, University of Pennsylvania; Inbal Nahum-Shani, University of Michigan; Daniel Almirall, University of Michigan
9:35 AM

ESTIMATING TREATMENT IMPORTANCE in MULTIDRUG-RESISTANT TUBERCULOSIS USING TARGETED LEARNING: AN OBSERVATIONAL INDIVIDUAL PATIENT DATA NETWORK META-ANALYSIS
Guanbo Wang, McGill University; Mireille Schnitzer, University of Montreal; Andrea Benedetti, Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre
10:35 AM

Multiply Robust Estimation of Causal Quantile Treatment Effects
Yuying Xie, University of Waterloo; Cecilia Cotton, University of Waterloo; Yeying Zhu, University of Waterloo
10:50 AM

Inference on Treatment Effect Modification by Marker Response in a Baseline Surrogate Measure Three-Phase Sampling Design
Michal Juraska, Fred Hutchinson Cancer Research Center; Ying Huang, Fred Hutchinson Cancer Research Center; Peter Gilbert, Fred Hutchinson Cancer Research Center
10:50 AM

Achieving Optimal Power of Logrank Test with Random Treatment Time-Lag Effect
Zhenzhen Xu , FDA; Yongsoek Park, Unversity of Pittsburgh; Boguang Zhen, FDA; Bin Zhu, NIH/NCI
11:00 AM

Improved Doubly Robust Estimation in Learning Individualized Treatment Rules
Yinghao Pan, Fred Hutchinson Cancer Research Center; Yingqi Zhao, Fred Hutchinson Cancer Research Center
11:05 AM

Use of Piecewise Weighted Log-Rank Test for Trials with Delayed Treatment Effect
Boguang Zhen, FDA; Zhenzhen Xu , FDA; Bin Zhu, NIH/NCI; Yongsoek Park, Unversity of Pittsburgh
11:25 AM

Embedding Observational Studies into Hypothetical Fractional-Factorial Experiments
Nicole Pashley, Harvard University; Marie-Abele Bind, Harvard University
11:35 AM

Gaussian Process Propensity Scores for Multiple Treatment Regimes
Brian Vegetabile, UC Irvine; Daniel L. Gillen, University of California, Irvine; Hal Stern, University of California, Irvine
11:50 AM

Estimating Causal Effect by Difference in Difference via Random Forest
Tomoshige Nakamura, Graduate School of Science and Technology, Keio University; Mihoko Minami, Keio University
12:05 PM

Improving Our Understanding of Dynamic Group-Based Interventions for Treating Depression and Substance Use Disorders
Susan M Paddock, RAND Corporation; Bing Han, RAND Corporation; Lane Burgette, RAND Corporation
2:05 PM

Studentized Sensitivity Analysis in Paired Observational Studies
Colin Fogarty, Massachusetts Institute of Technology
2:05 PM

Considering Delayed Treatment Effect in Trial Designs with Survival Endpoints
Kaushal Mishra, Novartis Oncology Pharmaceuticals; Kalyanee Viraswami Appanna, Novartis Pharmaceuticals
2:20 PM

A Parametric Multiple Comparison Procedure for Clinical Trials with Planned Evaluation of Treatment Effect in Pre-Defined Subgroups and Interim Analyzes
Liang Fang, MyoKardia; Ron Yu, Gilead Sciences, Inc.; Zhishen Ye, Gilead Sciences; Neby Bekele, Gilead Sciences; Ming Lin, Gilead Sciences
3:05 PM

Innovative Approaches to Deal with Delayed Treatment Effect, Cure Fraction and Treatment Switching in Time-To-Event Data in Cancer Immuno-Therapies
Carl Di Casoli, Halozyme Therapeutics; Alessandro Previtali, Celgene; Jonathan Jaeger, Celgene; Marie-Laure Casaebaig, Celgene
3:05 PM

A Simulation-Based Comparison Study About Different Methods Adjusting for the Bias of Treatment Non-Adherence
Jia Jia, AbbVie; Ying Zhang, Penn State College of Medicine; Jane Qian, Abbvie
3:20 PM

Predictive Probability on Interim Analysis of Time-To-Event Endpoints with Delayed Treatment Effects
Matt Rosales, Astellas; Kentaro Takeda, Astellas Pharma Global Development, Inc.
3:35 PM

Statistical Methodologies to Detect Ineffective Regional Treatment Effect in a Multiregional Trial
Hsiao-Hui Tsou, National Health Research Institutes; Yu-Chieh Cheng, National Health Research Institutes; Chin-Fu Hsiao, National Health Research Institutes
3:35 PM

Tuesday, 07/31/2018

The Role of Mobile Health in Precision Medicine
Susan Murphy, Harvard University

Defining a More Powerful Endpoint in a Longitudinal Trial with information of correlation coefficient
Ruji Yao; qing li, merck; wen-chi wu, merck

Preventing False Discovery of Heterogeneous Treatment Effect Subgroups in Randomized Trials
Joseph Rigdon, Stanford University; Michael Baiocchi, Stanford University; Sanjay Basu, Stanford University School of Medicine

Use of Propensity Score and Disease Risk Score for Multiple Treatments with Time-To-Event Outcome
DI ZHANG, University of Pittsburgh; Jessica Kim, Division of Biometrics VII/Office of Biostatistics/CDER, FDA

A Comparison of MI and MMRM for Treatment of Missing Data
Lori Davis, QST Consultations

Sample Size in Adaptive Design with Treatment Selection
Zejiang Yang, Syneos Health

Online Local Q-Learning
Lili Wu, NCSU; Eric Laber, North Carlina State University

SuperLearning and Tree-Regression for Developing Treatment Rules That Optimize Health Outcomes
Andre Kurepa Waschka, University of California, Berkeley

Practical Determining the Late Effect Parameter in Fleming-Harrington Test When a Delayed Treatment Effect Is Predicted
Yuichiro Kaneko, Astellas Pharma; Satoshi Morita, Kyoto University

Performance Comparison of Post-Hoc Subgroup Search Algorithms for Clinical Trials
Victor Talisa, University of Pittsburgh; (Joyce) Chung-Chou H. Chang, University of Pittsburgh

A Joint Model of Opioid Treatment Admissions and Deaths for Adults and Adolescents in Ohio Counties
David Kline, Ohio State University; Staci Hepler, Wake Forest University

Causal Inference with Complex Surveys: a Comparison of Propensity Score Based Methods
Daniele Bottigliengo, Università degli Studi di Padova; Ileana Baldi, Università degli Studi di Padova; Corrado Lanera, Università degli Studi di Padova; Dario Gregori, Università degli Studi di Padova; Paola Berchialla, Università degli Studi di Torino

Targeted Maximum Likelihood Estimation of Causal Effects Based on Observing a Single Time Series
Ivana Malenica; Mark van der Laan, UC Berkeley

Design Considerations When Comparing Control, Treatment, and Treatment Plus in Randomized Trials
Abigail Shoben, Ohio State University

Calculating a Generated Effect Modifier (GEM) for Treatment Selection Based on Imaging Data
Todd Ogden, Columbia University; Hyung Park, Columbia University; Eva Petkova, NYU School of Medicine; Thaddeus Tarpey, Wright State University
8:35 AM

The Myth of Making Inference for Overall Treatment Efficacy with Data from Multiple Studies via Meta-Analysis
Brian Claggett, Harvard Medical School
8:55 AM

A Joint Model of Opioid Treatment Admissions and Deaths for Adults and Adolescents in Ohio Counties
David Kline, Ohio State University; Staci Hepler, Wake Forest University
9:15 AM

BAYESMETAB: TREATMENT of MISSING VALUES in METABOLOMIC STUDIES USING a BAYESIAN MODELING APPROACH
Jasmit Shah, Aga Khan University Hospital; Guy Brock, Ohio State University College of Medicine; Jeremy Gaskins, University of Louisville
9:35 AM

Performance Comparison of Post-Hoc Subgroup Search Algorithms for Clinical Trials
Victor Talisa, University of Pittsburgh; (Joyce) Chung-Chou H. Chang, University of Pittsburgh
9:40 AM

Regression Splines and Multi-Group Propensity Score Weighting for the Study of Surgical Volume-Outcome Relationships
Jennifer Cooper, Nationwide Children's Hospital
9:55 AM

Semiparametric Single-Index Models for Optimal Treatment Regimes with Censored Outcomes
Jin Wang, University of North Carolina at Chapel Hill; Danyu Lin, University of North Carolina; Donglin Zeng, UNC Chapel Hill
10:35 AM

Inference on Average Treatment Effect with Repeated Data Splitting in High Dimensions
Jingshen Wang, University of Michigan; Xuming He, University of Michigan; Gongjun Xu, University of Michigan
10:35 AM

Estimating Causal Effects of Organ Transplantation Treatment Regimes
David Michael Vock, University of Minnesota; Jeffrey Boatman, Gustavus Adolphus College
10:35 AM

Targeted Maximum Likelihood Estimation of Causal Effects Based on Observing a Single Time Series
Ivana Malenica; Mark van der Laan, UC Berkeley
10:35 AM

Using Q-Learning Method in Identify Optimal Treatment Regime
Haocheng Li, Hoffmann-La Roche Limited (Roche Canada); Vincent Shen, Hoffmann-La Roche Limited (Roche Canada); Hao Xu, Hoffmann-La Roche Limited (Roche Canada); Sylvia Hu, Roche-Genentech
10:35 AM

A Robust Approach to Sample Size Calculation in Cancer Immunotherapy Trials with Delayed Treatment Effect
Ting Ye, University of Wisconsin-Madison; Menggang Yu, University of Wisconsin-Madison
10:55 AM

Propensity Score Methods for Studies with Hierarchical Data Structure and Continuous Treatments: Application to Childhood Obesity Interventions in Los Angeles County
Justin R Williams, UCLA; Catherine Crespi, University of California, Los Angeles; May Wang, University of California, Los Angeles
10:55 AM

What Is the Most Appropriate Time Point Cut to Give Treatment Under Emergency Setting?
Ja-An Lin, Food & Drug Administration; Laura Yee, NIH; Pei He, Genetech Inc
11:05 AM

Estimation and Optimization of Composite Outcomes
Daniel J Luckett, University of North Carolina at Chapel Hill; Eric Laber, North Carlina State University; Michael Kosorok, University of North Carolina at Chapel Hill
11:15 AM

Ensemble Learning for Estimating Individualized Treatment Effects in Student Success Studies
Richard Levine, San Diego State University; Joshua Beemer, San Diego State University; Juanjuan Fan, San Diego State University
11:20 AM

Assessment of Treatment Effects in Single Cases and Small Groups: Assumptions, Logic, Algorithm, Computations
Lev Sverdlov
11:20 AM

Developing Genomic Biomarker to Guide Personalized Patient Management in Oncology: Validity and Utility of Clinical Diagnostic Applications
Michael Crager, Genomic Health; Ruixiao Lu, Genomic Health, Inc.
11:25 AM

Practical Determining the Late Effect Parameter in Fleming-Harrington Test When a Delayed Treatment Effect Is Predicted
Yuichiro Kaneko, Astellas Pharma; Satoshi Morita, Kyoto University
11:35 AM

The Statistical Performance of Matching-Adjusted Indirect Comparisons
David Cheng, Harvard University; Rajeev Ayyagari, Analysis Group; Timothy Juday, Allergan; Angelina Villasis Keever, Janssen Research and Development; James Signorovitch, Analysis Group
11:35 AM

Individualized Treatment Effects with Censored Data via Fully Nonparametric Bayesian Accelerated Failure Time Models
Nicholas Henderson, Johns Hopkins University
11:35 AM

Estimation of Treatment Effect in Enriched Clinical Trials: Application to Multiple Sclerosis
Rachel MacKay Altman, Simon Fraser University
11:35 AM

Network Meta-Analysis: On the Use of the Standard Contrast-Based Approach in Disconnected Networks
Audrey Béliveau, University of Waterloo; Paul Gustafson, University of British Columbia
11:50 AM

Design Considerations When Comparing Control, Treatment, and Treatment Plus in Randomized Trials
Abigail Shoben, Ohio State University
12:05 PM

What Do We Know About Estimators for the Treatment Policy Estimand?
Elena Polverejan, Janssen R&D; Vladimir Dragalin, Janssen R&D
2:05 PM

Choosing the Primary Efficacy Analysis for a Randomized Clinical Trial with Competing Risks
Eric Leifer, National Heart, Lung, and Blood Institute; James Troendle, National Institutes of Health; Lauren Kunz, National Heart, Lung, and Blood Institute
2:05 PM

Measuring Association Between Times from Treatment Initiation to Viral Failure and Regimen Change in HIV-Infected Persons
Svetlana K. Eden, Vanderbilt University School of Medicine; Bryan E Shepherd, Vanderbilt University School of Medicine; Chun Li, Case Western Reserve University, Institute for Computational Biology
2:25 PM

Assessing Sensitivity to Unmeasured Confounding with Multiple Treatments and a Binary or Survival Outcome: A Bayesian Approach
Liangyuan Hu, Icahn School of Medicine at Mount Sinai; Chenyang Gu, Harvard Medical School; Michael Lopez , Skidmore College
2:30 PM

Inference on the Treatment Effect in Non-Randomized Pretest-Posttest Studies with Missing Data: An Empirical Likelihood Approach
Shixiao Zhang, University of Waterloo; Peisong Han, University of Michigan; Changbao Wu, University of Waterloo
2:35 PM

Assessing Individual and Disseminated Causal Package Effects in Network HIV Treatment and Prevention Trials
Ashley Buchanan, University of Rhode Island; Donna Spiegelman, Harvard T.H. Chan School of Public Health; Sten Vermund, Yale University; Samuel Friedman, National Development and Research Institutes, Inc.; Judith Lok, Harvard T.H. Chan School of Public Health
2:45 PM

Undiluting the Treatment Effect
Thomas Permutt, Food and Drug Administration
2:55 PM

Evaluation of Therapeutic Effect in Clinical Study Using Companion Diagnostic Device for Patient Screening
Jeng Mah, Beckman Coulter
3:05 PM

Wednesday, 08/01/2018

Exploring Treatment Heterogeneity Using Propensity Scores
Maozhu Dai, University of California, Irvine; Hal Stern, University of California, Irvine

A Nonlinear Mixed Effects Model to Estimate Declines in Mycobacterium Tuberculosis DNA Burden from Viable Bacteria During Tuberculosis Treatment
Camille Moore, National Jewish Health; Nicholas Walter, University of Colorado Denver

Treatment Effect Estimation in Subgroups: a Comparative Study
Weihua Cao, Novartis Pharmaceutical Corp; Bjoern Holzhauer, Novartis Pharma AG; Steffen Ballerstedt, Novartis Pharma AG; Dong Xi, Novartis Pharmaceuticals; Ieuan Jones, Novartis Pharma AG

Further Extensions of the Two-Stage Randomized Trial Design for Testing Treatment, Self-Selection and Treatment Preference Effects to Include Count Outcomes
Denise Esserman, Yale University; Yu Shi, Yale University

Subgroup Selection in Adaptive Signature Designs of Confirmatory Clinical Trials
Zhiwei Zhang, University of California at Riverside
8:35 AM

Incorporating Intermediary Information in Cox Models of Randomized Clinical Trials: The Information Balanced Intermediary Cox Model
James Troendle, National Institutes of Health; Eric Leifer, National Heart, Lung, and Blood Institute; Lauren Kunz, National Heart, Lung, and Blood Institute; Song Yang, NHLBI/NIH
8:50 AM

Q-Learning with Missing Data
Lin Dong, North Carolina State University; Eric Laber, North Carlina State University
8:55 AM

Mortality Prediction with Multiple Unordered Treatments for Aortic Valve Replacement
Samrachana Adhikari, Harvard Medical School; Sherri Rose, Harvard Medical School; Sharon-Lise Normand, Harvard University; Jordan Bloom, Harvard Medical School; David Shahian, Harvard Medical School; Jake Spertus, Harvard Medical School
8:55 AM

A Probability Based Method for Selecting the Optimal Personalized Treatment from Multiple Treatments
Karunarathna B Kulasekera, University of Louisville; Chathura Siriwardhana, University of Hawaii; Somnath Datta, University of Florida
9:15 AM

Weighted Log-Rank Test for Time-To-Event Data in Immunotherapy Trials with Random Delayed Treatment Effect and Cure Rate
Shufang Liu, Astellas Pharma; Chenghao Chu, Indiana University, Fairbanks School of Public Health; Alan Rong, Data Science, Astellas Pharma Inc.
9:35 AM

Constructing Stabilized Dynamic Treatment Regimes
Guanhua Chen, University of Wisconsin-Madison; Ruoqing Zhu, University of Illinois Urbana-Champaign; Yingqi Zhao, Fred Hutchinson Cancer Research Center; Yingye Zheng, Fred Hutchinson Cancer Research Center
9:35 AM

Heterogeneous Treatment Effect Estimation through Deep Learning
Ran Chen, Wharton; Hanzhong Liu, Center for Statistical Science, Tsinghua University
9:35 AM

Selection of the Optimal Personalized Treatment from Multiple Treatments with Multivariate Outcome Measures
Somnath Datta, University of Florida; Chathura Siriwardhana, University of Hawaii; Karunarathna B Kulasekera, University of Louisville
9:55 AM

Assessment of Treatment Effect on Overall Survival in the Presence of Treatment Switching: a Bridging Approach Across Various Modeling Methods
Yiyun Tang, Pfizer, Inc.; Selaru Paulina, Pfizer Inc.; Xin Huang, Pfizer Inc.
10:05 AM

Matching Methods for Causal Inference with Time-Series Cross-Section Data
Kosuke Imai, Princeton University; Erik Wang, Princeton University; In Song Kim, MIT
10:35 AM

Sharp Instruments for Classifying Compliers and Generalizing Causal Effects
Edward Kennedy, Carnegie Mellon University
10:35 AM

Measuring the Individual Benefits of a Medical or Behavioral Treatment Using Generalized Linear Mixed-Effects Models
Francisco Diaz, The University of Kansas Medical Center
11:05 AM

Uniformity of Personalized Treatment
Georgiy Bobashev, Research Triangle Institute; Barry Eggleston, RTI International; Benjamin Carper, RTI International
11:05 AM

Scalar-On-Function Prediction Models with Missing Covariates: Applications in Depression Research Using EEG and Clinical Data
Adam Ciarleglio, Columbia University and the New York State Psychiatric Institute; Eva Petkova, NYU School of Medicine
11:15 AM

A Robust and Efficient Approach to Causal Inference Based on Sparse Sufficient Dimension Reduction
Shujie Ma, UC Riverside-Dept of Statistics
11:15 AM

Group Sequential Tests of Treatment Effect on Survival and Cumulative Incidence at a Fixed Time Point
Michael Martens, The Emmes Corporation; Brent Logan, Medical College of Wisconsin
11:35 AM

Improving Testing and Description of Treatment Effect in Clinical Trials with Time-To-Event Outcomes
Song Yang, NHLBI/NIH
11:50 AM

Causal Inference Under Unmodeled and All-Encompassing Interference
Fredrik Sävje, Yale University
2:25 PM

Real-Time, Within-Person Randomization Using a Bandit Algorithm in a Clinical Trial
Susan Murphy, Harvard University
2:55 PM

Thursday, 08/02/2018

Dynamic Treatment Regimens for Superbug Infections
Dean Follmann, NIAID
8:35 AM

Inferential Challenges in Machine Learning and Precision Medicine
Michael Kosorok, University of North Carolina at Chapel Hill
8:35 AM

A Non-Parametric Statistical Test of Null Treatment Effect in Sub-Populations
Lin Taft, GSK; Changyu Shen, Beth Israel Deaconess Medical Center, Harvard Medical School
8:35 AM

Beware On-Treatment Safety Analysis
Janet Wittes, Statistics Collaborative; Fred Yang, Innomed Consulting
8:35 AM

Uncertainty Quantification of Treatment Regime in Precision Medicine by Confidence Distributions
Minge Xie, Rutgers University; Yilei Zhan, Rutgers University; Sijian Wang, Rutgers University
9:00 AM

Mathematical Modeling Identifies Optimum Lapatinib Dosing Schedules for the Treatment of Glioblastoma Patients
Shayna Stein, Harvard University; Franziska Michor, Dana Farber Cancer Institute
9:05 AM

Multi-Response Based Personalized Treatment Selection for Multiple Treatments
Chathura Siriwardhana, University of Hawaii; Karunarathna B Kulasekera, University of Louisville
9:05 AM

Treatment Heterogeneity and Treatment Eligibility Estimations Using Random Forest Methods
Min Lu, University of Miami; Eugene H. Blackstone, Cleveland Clinic; Hemant Ishwaran, University of Miami
9:35 AM

Predicting the Long-Term Exposure in Acute Treatment of Migraine Using a Nonhomogeneous Poisson Process with Random Effects
Kaifeng Lu
9:35 AM

Lasso Estimation of Hierarchical Interactions for Analyzing Heterogeneous Treatment Effect
Yu Du, Johns Hopkins Bloomberg School of Public Health; Ravi Varadhan, Johns Hopkins University
9:50 AM

Optimal Treatment Recommendation via Subgroup Identification in Randomized Control Trials
Yang (Grace) Zhao, Gilead Sciences; Haoda Fu, Eli Lilly and Company
10:05 AM

Evaluation of Treatment Effect: Beyond Traditional Subgroups
Yeh-Fong Chen, US FDA
10:55 AM

Marginal Structural Models to Estimate the Effects of Time-Varying Treatments on Clustered Outcomes in the Presence of Interference
Alisa Stephens-Shields, University of Pennsylvania; Jiwei He, US Food and Drug Administration; Marshall Joffe, University of Pennsylvania
10:55 AM

Bias-Corrected Estimation of Treatment Effects in Biomarker-Based Adaptive Subgroup Analysis: New Approach Based on Randomized Tests with Smooth Rejection Function
Kiichiro Toyoizumi, Shionogi Inc.; Shigeyuki Matsui, Nagoya University
11:05 AM

Biomarker Guided Phase II Two-Stage Design for Targeted Therapy
Zheyu Wang, Johns Hopkins University; Fujun Wang, Medimmune; Chenguang Wang, Johns Hopkins University; Gary Rosner, Johns Hopkins University; Jianliang Zhang, Medimmune; Hao Wang, Johns Hopkins University; Li Shi, Medimmune
11:25 AM

Methodological Considerations for the Analysis of Relative Treatment Effects in Multi-Drug-Resistant Tuberculosis from Fused Observational Studies
Mireille Schnitzer, University of Montreal; Andrea Benedetti, Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre; Guanbo Wang, McGill University; Arman Alam Siddique, McMaster University; Asma Bahamyirou, Université de Montréal
11:35 AM

Discovering Effect Modification in Observational Studies
Dylan Small, University of Pennsylvania; Jesse Yenchih Hsu, University of Pennsylvania; Paul Rosenbaum, University of Pennsylvania; Kwonsang Lee, Harvard University; Jose Zubizarreta, Harvard University; Jeffrey Silber, University of Pennsylvania
11:50 AM

Selecting Among Treatments with Two Bernoulli Endpoints
Elena M Buzaianu, University of North Florida; Pinyuen Chen, Syracuse University; Lifang Hsu, Le Moyne College
11:50 AM

Understand International Differences in Treatment Effect
Li Chen, Amgen
11:55 AM

JSM 2018 Online Program

Keyword Search

American Statistical Association